EZZ Life Science Holdings (ASX:EZZ) has entered a manufacturing agreement with US-based GLSP, to produce nutritional supplements for the North American market, according to a Tuesday filing with the Australian bourse.
GLSP will manufacture EZZ-branded products in compliance with the US Food and Drug Administration regulations and under ISO standards, with third-party testing for microbiological and heavy metals safety, the filing added.
The agreement stipulates a production timeline of six to 10 weeks, starting from the receipt of all production requirements and the initial payment, while EZZ will retain full intellectual property rights, including patents and formulations.
Shares of the company fell 6% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。